Novel chimeric somatostatin analogs: facts and perspectives.
about
Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromeGuidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Octreotide long-acting repeatable for acromegaly.Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.Molecular basis of pharmacological therapy in Cushing's disease.Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
P2860
Q27021274-7CD4C156-2766-4B96-97D8-6FC24D6FAC19Q33753449-F00966C5-FC84-4528-AC44-04AB1C543CE1Q34057477-DF07898E-4DA7-4DE2-8D04-902356DE368CQ35650633-7C91B01C-CF05-4BEC-8E0D-A85A2B3678A4Q37314246-777F956B-1A92-496D-8300-F934A28F04A0Q37321948-1C31EEA8-45B7-46E0-8E8A-EC0E338141B0Q37990556-51796AD8-56CF-4148-A096-2CD430C5DE1AQ38132768-A2D43410-876F-478F-95F8-64B4E88F1523Q38165863-A4F64C12-64EA-4717-B809-5B94FD589803Q39024218-D4019E05-1A16-4D65-9C24-27BA9699FB4FQ39962632-19EEACB8-FCAD-4370-B588-2DA2AFF967BBQ42457597-C675B494-6B7D-4517-A10A-9E27739F396EQ43078115-684CF21D-D1C7-488D-82C8-386F0FF3C219Q54353594-9DF651C4-7324-4394-915B-A55CB0C4A3CD
P2860
Novel chimeric somatostatin analogs: facts and perspectives.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Novel chimeric somatostatin analogs: facts and perspectives.
@en
type
label
Novel chimeric somatostatin analogs: facts and perspectives.
@en
prefLabel
Novel chimeric somatostatin analogs: facts and perspectives.
@en
P2093
P50
P356
P1476
Novel chimeric somatostatin analogs: facts and perspectives
@en
P2093
Alberto Rebora
Francesco Minuto
Marica Arvigo
Philippe Jaquet
P356
10.1530/EJE.1.02356
P478
156 Suppl 1
P577
2007-04-01T00:00:00Z